PMID- 25954034 OWN - NLM STAT- MEDLINE DCOM- 20160428 LR - 20220129 IS - 1460-2083 (Electronic) IS - 0964-6906 (Print) IS - 0964-6906 (Linking) VI - 24 IP - 14 DP - 2015 Jul 15 TI - The pro-domains of neurotrophins, including BDNF, are linked to Alzheimer's disease through a toxic synergy with Abeta. PG - 3929-38 LID - 10.1093/hmg/ddv130 [doi] AB - Brain-derived neurotrophic factor (BDNF) has a crucial role in learning and memory by promoting neuronal survival and modulating synaptic connectivity. BDNF levels are lower in the brains of individuals with Alzheimer's disease (AD), suggesting a pathogenic involvement. The Drosophila orthologue of BDNF is the highly conserved Neurotrophin 1 (DNT1). BDNF and DNT1 have the same overall protein structure and can be cleaved, resulting in the conversion of a full-length polypeptide into separate pro- and mature-domains. While the BDNF mature-domain is neuroprotective, the role of the pro-domain is less clear. In flies and mammalian cells, we have identified a synergistic toxic interaction between the amyloid-beta peptide (Abeta1-42) and the pro-domains of both DNT1 and BDNF. Specifically, we show that DNT1 pro-domain acquires a neurotoxic activity in the presence of Abeta1-42. In contrast, DNT1 mature-domain is protective against Abeta1-42 toxicity. Likewise, in SH-SY5Y cell culture, BDNF pro-domain is toxic only in the presence of Abeta1-42. Western blots indicate that this synergistic interaction likely results from the Abeta1-42-induced upregulation of the BDNF pro-domain receptor p75(NTR). The clinical relevance of these findings is underlined by a greater than thirty fold increase in the ratio of BDNF pro- to mature-domains in the brains of individuals with AD. This unbalanced BDNF pro:mature-domain ratio in patients represents a possible biomarker of AD and may offer a target for therapeutic intervention. CI - (c) The Author 2015. Published by Oxford University Press. FAU - Lim, Jung Yeon AU - Lim JY AD - Department of Genetics, University of Cambridge, Downing Street, Cambridge CB2 3EH, UK. FAU - Reighard, Charles P AU - Reighard CP AD - Department of Biochemistry, University of Cambridge, Tennis Court Road, Cambridge CB2 1GA, UK and. FAU - Crowther, Damian C AU - Crowther DC AD - Department of Genetics, University of Cambridge, Downing Street, Cambridge CB2 3EH, UK, MedImmune Limited, Aaron Klug Building, Granta Park, Cambridge CB21 6GH, UK dcc26@cam.ac.uk. LA - eng GR - G0700990/MRC_/Medical Research Council/United Kingdom GR - 082604/2/07/Z/Wellcome Trust/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20150507 PL - England TA - Hum Mol Genet JT - Human molecular genetics JID - 9208958 RN - 0 (Amyloid beta-Peptides) RN - 0 (Brain-Derived Neurotrophic Factor) RN - 0 (Drosophila Proteins) RN - 0 (Genetic Markers) RN - 0 (Nerve Growth Factors) RN - 0 (Peptide Fragments) RN - 0 (amyloid beta-protein (1-42)) RN - 0 (neurotrophin 1, Drosophila) RN - 7171WSG8A2 (BDNF protein, human) RN - EC 2.7.10.1 (Receptor, trkB) SB - IM MH - Aged MH - Aged, 80 and over MH - Alzheimer Disease/*genetics MH - Amyloid beta-Peptides/genetics/*metabolism MH - Animals MH - Brain/metabolism MH - Brain-Derived Neurotrophic Factor/genetics/*metabolism MH - Cell Line, Tumor MH - Cell Survival MH - Drosophila/*genetics MH - Drosophila Proteins/genetics/*metabolism MH - Female MH - Genetic Markers MH - Humans MH - Male MH - Middle Aged MH - Nerve Growth Factors/genetics/*metabolism MH - Peptide Fragments/genetics/*metabolism MH - Protein Interaction Maps MH - Receptor, trkB/genetics/metabolism MH - Up-Regulation PMC - PMC4476443 EDAT- 2015/05/09 06:00 MHDA- 2016/04/29 06:00 PMCR- 2015/05/07 CRDT- 2015/05/09 06:00 PHST- 2015/01/20 00:00 [received] PHST- 2015/04/08 00:00 [accepted] PHST- 2015/05/09 06:00 [entrez] PHST- 2015/05/09 06:00 [pubmed] PHST- 2016/04/29 06:00 [medline] PHST- 2015/05/07 00:00 [pmc-release] AID - ddv130 [pii] AID - 10.1093/hmg/ddv130 [doi] PST - ppublish SO - Hum Mol Genet. 2015 Jul 15;24(14):3929-38. doi: 10.1093/hmg/ddv130. Epub 2015 May 7.